Myriad Illuminates High Court's Approach To Section 101

Law360, New York (July 8, 2013, 12:21 PM EDT) -- On June 13, 2013, the U.S. Supreme Court handed down its long-awaited decision in Association for Molecular Pathology v. Myriad Genetics Inc., in which it found claims to isolated DNA not patent eligible under 35 U.S.C. § 101. The Myriad opinion is interesting not only in its own right, but also for how it illuminates the Supreme Court’s recent approach to cases involving Section 101, an issue with a long and complex history reflecting a variety of legal tests and approaches.

An examination of Myriad together...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.